HC Wainwright & Co. Initiates Coverage On iBio with Buy Rating, Announces Price Target of $7

HC Wainwright & Co. has initiated coverage on iBio (NASDAQ: IBIO) with a Buy rating and set a price target of $7 for the stock. This marks a positive outlook for the company as it enters a new phase of analyst coverage.